Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | CBFB | Q13951 | 2/20 | 0.43 |
| ▸ | FYN | P06241 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516644 | 1.00 | KDM1A (0.55) | KDM1ALDHACYP11B1CYP11B2CASP3 | |
| SCHEMBL15349769 | 0.83 | CBFB (0.48) | KDM1ALDHACYP11B1CYP11B2CASP3 | |
| SCHEMBL24784608 | 0.81 | KDM1A (0.40) | KDM1ALDHACYP11B1CYP11B2FYN | |
| SCHEMBL8019903 | 0.79 | CASP3 (0.64) | KDM1ACYP11B1CYP11B2CASP3SENP8 | |
| SCHEMBL26784179 | 0.79 | ABL1 (0.49) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL30103132 | 0.79 | KDM1A (0.47) | KDM1ALDHAGRM5NPC1RAB9A | |
| SCHEMBL24785377 | 0.79 | KDM1A (0.47) | KDM1ALDHAGRM5NPC1RAB9A | |
| SCHEMBL24453569 | 0.76 | CASP3 (0.52) | KDM1ACYP11B1CYP11B2CASP3SENP8 | |
| SCHEMBL4116531 | 0.75 | BRAF (0.49) | FYNNPC1RAB9A | |
| SCHEMBL24785040 | 0.75 | KDM1A (0.55) | KDM1ACYP11B1CYP11B2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| WO-2023158221-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | 주식회사 카나프테라퓨틱스 | 2023-08-24 | — | — | WO | disclosed |
| CN-116529238-A | Novel prostaglandin E 2 Compounds with receptor inhibiting activity and uses thereof | 治纳辅医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | KDM1A 4527/4885LDHA 3755/4885CYP11B1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.